Meta-analysis quantifies pre-diagnosis weight loss in pancreatic cancer patients

This systematic review and meta-analysis synthesized data from 25,971 participants with pancreatic cancer to quantify pre-diagnosis weight loss. The primary outcome was weight loss in kilograms and body mass index (BMI) change. The analysis revealed an average weight loss of 5.9 kg (95% CI 4.7 to 7.1) and a BMI decrease of 2.5 kg/m² (95% CI -3.0 to -2.1) prior to diagnosis. These findings provide a quantitative reference for expected weight loss in this patient population.

The certainty of the evidence was rated as moderate, primarily due to high heterogeneity between the included studies (I² = 99.2% for weight loss, I² = 82.6% for BMI change). This substantial variability suggests differences in study populations, methodologies, or measurement techniques, which clinicians should consider when applying these results. The meta-analysis did not report on safety outcomes, as the focus was on pre-diagnostic weight change rather than therapeutic intervention.

From a clinical practice perspective, these results offer a valuable benchmark for expected weight loss in individuals who later develop pancreatic cancer. This can aid in refining early detection models and clinical suspicion during patient evaluations. However, the analysis is limited to observational data on pre-diagnostic weight change and does not establish causality between weight loss and cancer development.

The limitations noted by the authors include the high heterogeneity, which may affect the generalizability of the pooled estimates. Despite this, the consistent direction of effect across studies supports the observed weight loss trend. The review did not investigate secondary outcomes or safety data, as these were outside the scope of the included studies.

For healthcare providers, this meta-analysis underscores the importance of unexplained weight loss as a potential early sign of pancreatic cancer. While not diagnostic, the quantified weight loss can inform clinical judgment and prompt further investigation in at-risk patients. The findings should be interpreted with caution due to the moderate certainty of evidence and high heterogeneity.

In summary, this meta-analysis provides a robust estimate of pre-diagnosis weight loss in pancreatic cancer patients, which can be integrated into clinical practice to improve early detection efforts. The results highlight the need for further research to understand the mechanisms behind this weight loss and its role in cancer pathogenesis.